Phibro Animal Health (NASDAQ:PAHC) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

Other analysts have also recently issued research reports about the stock. Barclays upped their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. JPMorgan Chase & Co. assumed coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Phibro Animal Health has an average rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Stock Down 1.0 %

Shares of NASDAQ PAHC opened at $20.52 on Friday. Phibro Animal Health has a 52-week low of $10.03 and a 52-week high of $25.98. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The stock has a market cap of $831.12 million, a P/E ratio of 47.72, a P/E/G ratio of 0.58 and a beta of 0.53. The firm has a 50 day moving average price of $23.01 and a 200 day moving average price of $20.96.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th were given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 2.34%. The ex-dividend date was Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio is presently 111.63%.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds have recently made changes to their positions in the business. Sofinnova Investments Inc. acquired a new position in Phibro Animal Health during the second quarter worth $3,975,000. Geode Capital Management LLC raised its holdings in Phibro Animal Health by 5.7% during the third quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after acquiring an additional 27,201 shares in the last quarter. Barclays PLC boosted its position in Phibro Animal Health by 25.7% during the third quarter. Barclays PLC now owns 143,337 shares of the company’s stock valued at $3,228,000 after purchasing an additional 29,271 shares during the last quarter. Acadian Asset Management LLC grew its stake in Phibro Animal Health by 6.3% in the second quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after purchasing an additional 42,299 shares in the last quarter. Finally, Algert Global LLC raised its stake in shares of Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after purchasing an additional 59,850 shares in the last quarter. 99.34% of the stock is owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.